Recent Quotes (30 days)

You have no recent quotes
chg | %

AEterna Zentaris Inc. (USA)  

(Public, NASDAQ:AEZS)   Watch this stock  
Find more results for AEZS
-1.36 (-12.30%)
After Hours: 9.74 +0.04 (0.41%)
Nov 30, 7:59PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.25 - 10.46
52 week 0.04 - 88.90
Open 9.43
Vol / Avg. 3.12M/2.18M
Mkt cap 72.67M
P/E     -
Div/yield     -
EPS -27.75
Shares 632.72M
Beta 1.76
Inst. own 3%
Nov 6, 2015
Q3 2015 AEterna Zentaris Inc Earnings Call
Nov 5, 2015
Q3 2015 AEterna Zentaris Inc Earnings Release
Sep 9, 2015
AEterna Zentaris Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -8902.31% -156245.50%
Operating margin -4335.84% -339954.50%
EBITD margin - -309345.50%
Return on average assets -116.39% -32.24%
Return on average equity -555.74% -108.96%
Employees 88 -
CDP Score - -


C/O Norton Rose Fulbright Canada Llp 1 Place Ville Marie, Suite 2500
+1-514-8474516 (Phone)
+1-418-9489191 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company engaged in developing treatments in oncology, endocrinology and women's health. The Company has three wholly owned direct and indirect subsidiaries: AEZS GmbH, based in Frankfurt, Germany, Zentaris IVF GmbH, a direct wholly owned subsidiary of AEZS Germany based in Frankfurt, Germany, and Aeterna Zentaris, Inc. Its drug development efforts are focused on two compounds, zoptarelin doxorubicin and Macrilen, which are in clinical development, and on two oncology compounds (an Erk inhibitor and Luteinizing Hormone-Releasing Hormone-disorazol Z product candidates), which are in pre-clinical development. Zoptarelin doxorubicin represents a hybrid molecule composed of a synthetic peptide carrier and a chemotherapy agent, doxorubicin. Macrilen (macimorelin acetate) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor.

Officers and directors

David A. Dodd Chairman of the Board, President, Chief Executive Officer
Age: 65
Bio & Compensation  - Reuters
Dennis Turpin CA Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Philip Allen Theodore Senior Vice President, Chief Administrative Officer, General Counsel
Age: 61
Bio & Compensation  - Reuters
Richard Sachse M.D., Ph.D. Senior Vice President, Chief Scientific Officer, Chief Medical Officer
Bio & Compensation  - Reuters
Jude Dinges Chief Commercial Officer, Senior Vice President
Bio & Compensation  - Reuters
Keith Santorelli Vice President - Finance
Bio & Compensation  - Reuters
Michael Teifel Vice President - Non-Clinical Sciences
Bio & Compensation  - Reuters
Juergen H. L. Ernst Lead Independent Director
Age: 76
Bio & Compensation  - Reuters
M. Marcel Aubut QC Independent Director
Bio & Compensation  - Reuters
Jose P. Dorais Independent Director
Bio & Compensation  - Reuters